Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, Madan RA, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL.

AJR Am J Roentgenol. 2019 Oct 15:1-9. doi: 10.2214/AJR.19.21264. [Epub ahead of print]

PMID:
31613660
2.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.

NPJ Breast Cancer. 2019 Oct 8;5:34. doi: 10.1038/s41523-019-0130-x. eCollection 2019. Review.

3.

Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion.

Redman JM, Rhea LP, Brofferio A, Whelpley M, Gulley JL, Gatti-Mays ME, McMahon S, Cordes LM, Strauss J.

J Gastrointest Oncol. 2019 Oct;10(5):1010-1014. doi: 10.21037/jgo.2019.07.04.

4.

Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL.

Oncologist. 2019 Oct 10. pii: theoncologist.2018-0470. doi: 10.1634/theoncologist.2018-0470. [Epub ahead of print]

PMID:
31601731
5.

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J.

Oncologist. 2019 Oct 8. pii: theoncologist.2019-0608. doi: 10.1634/theoncologist.2019-0608. [Epub ahead of print]

PMID:
31594913
6.

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.

Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00176. Epub 2019 Sep 9.

7.

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marté JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL.

J Immunother Cancer. 2019 Sep 5;7(1):240. doi: 10.1186/s40425-019-0706-x.

8.

The role of lineage plasticity in prostate cancer therapy resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Jul 30. pii: clincanres.1423.2019. doi: 10.1158/1078-0432.CCR-19-1423. [Epub ahead of print]

PMID:
31363002
9.

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.

Cardis MA, Jiang H, Strauss J, Gulley JL, Brownell I.

BMC Cancer. 2019 Jun 4;19(1):539. doi: 10.1186/s12885-019-5759-1.

10.

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Aug 15;25(16):4933-4944. doi: 10.1158/1078-0432.CCR-19-0183. Epub 2019 May 20.

PMID:
31110074
11.

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.

Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS.

J Immunother Cancer. 2019 May 3;7(1):119. doi: 10.1186/s40425-019-0603-3.

12.

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, Dahut W, Pinto PA.

Urol Oncol. 2019 Jun;37(6):352.e25-352.e30. doi: 10.1016/j.urolonc.2019.01.012. Epub 2019 Apr 15.

PMID:
31000430
13.

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I.

Oncologist. 2019 Sep;24(9):1259-1269. doi: 10.1634/theoncologist.2018-0823. Epub 2019 Apr 17.

PMID:
30996010
14.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
15.

A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Redman JM, Rhea LP, Cordes L, Owens H, Madan RA, Bilusic M, Gulley JL, Lee JM, Dahut WL, Karzai F.

Clin Genitourin Cancer. 2019 Jun;17(3):e549-e552. doi: 10.1016/j.clgc.2019.02.005. Epub 2019 Feb 14. No abstract available.

PMID:
30850338
16.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
17.

A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL.

Oncotarget. 2018 Dec 28;9(102):37676-37688. doi: 10.18632/oncotarget.26481. eCollection 2018 Dec 28.

18.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.

19.

M7824: A promising new strategy to combat cancer immune evasion.

Gatti-Mays ME, Gulley JL.

Oncoscience. 2018 Aug 22;5(11-12):269-270. doi: 10.18632/oncoscience.451. eCollection 2018 Nov. No abstract available.

20.

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.

Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL.

J Immunother Cancer. 2019 Jan 16;7(1):12. doi: 10.1186/s40425-018-0459-y.

21.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):351-357. doi: 10.1001/jamaoncol.2018.5428.

22.

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.

Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, Gulley JL, Bilusic M.

J Immunother Cancer. 2018 Dec 18;6(1):150. doi: 10.1186/s40425-018-0473-0.

23.

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL.

J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.

24.

Product review: avelumab, an anti-PD-L1 antibody.

Collins JM, Gulley JL.

Hum Vaccin Immunother. 2019;15(4):891-908. doi: 10.1080/21645515.2018.1551671. Epub 2018 Dec 20.

25.

Vaccines as an Integral Component of Cancer Immunotherapy.

Schlom J, Gulley JL.

JAMA. 2018 Dec 4;320(21):2195-2196. doi: 10.1001/jama.2018.9511. No abstract available.

26.

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.

Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL.

J Immunother Cancer. 2018 Oct 22;6(1):111. doi: 10.1186/s40425-018-0424-9.

27.

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

Madan RA, Gulley JL.

J Natl Cancer Inst. 2019 Mar 1;111(3):219-220. doi: 10.1093/jnci/djy145. No abstract available.

28.
29.

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS.

Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.

PMID:
30197041
30.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5. No abstract available.

PMID:
30185415
31.

Pembrolizumab: patient selection or immune intensification?

Madan RA, Gulley JL.

Nat Rev Urol. 2018 Oct;15(10):593-594. doi: 10.1038/s41585-018-0076-z. No abstract available.

PMID:
30131600
32.

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.

Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.

PMID:
30131389
33.

White paper on microbial anti-cancer therapy and prevention.

Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G.

J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3.

34.

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.

Collins JM, Redman JM, Gulley JL.

Expert Rev Vaccines. 2018 Aug;17(8):697-705. doi: 10.1080/14760584.2018.1506332. Epub 2018 Aug 22. Review.

PMID:
30058393
35.

Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".

Bilusic M, Gulley JL.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx132. No abstract available.

36.

Avelumab: is it time to get excited?

Marciscano AE, Gulley JL, Kaufman HL.

Expert Rev Anticancer Ther. 2018 Sep;18(9):815-821. doi: 10.1080/14737140.2018.1493380. Epub 2018 Jul 2. No abstract available.

PMID:
29939083
37.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

38.

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Merino MJ, Pinto PA, Moreno V, Gil S, Schlom J, Gulley JL.

Hum Pathol. 2018 Aug;78:72-78. doi: 10.1016/j.humpath.2018.04.013. Epub 2018 Apr 30.

PMID:
29709495
39.

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.

J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.

40.

Perspectives on the clinical development of immunotherapy in prostate cancer.

Cordes LM, Gulley JL, Madan RA.

Asian J Androl. 2018 May-Jun;20(3):253-259. doi: 10.4103/aja.aja_9_18. Review.

41.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.

Cancer. 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.

42.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.

Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.

43.

Avelumab demonstrates promise in advanced NSCLC.

Marciscano AE, Gulley JL.

Oncotarget. 2017 Nov 13;8(61):102767-102768. doi: 10.18632/oncotarget.22418. eCollection 2017 Nov 28. No abstract available.

44.

Checkpoint and PARP inhibitors, for whom and when.

Lee JM, Gulley JL.

Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10. No abstract available.

45.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB.

Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5. Erratum in: Lancet Oncol. 2018 Jul;19(7):e335.

PMID:
29217288
46.

Combining immunotherapies for the treatment of prostate cancer.

Redman JM, Gulley JL, Madan RA.

Urol Oncol. 2017 Dec;35(12):694-700. doi: 10.1016/j.urolonc.2017.09.024. Review.

47.

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C.

Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.

48.

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J.

Oncotarget. 2017 Sep 8;8(43):75217-75231. doi: 10.18632/oncotarget.20680. eCollection 2017 Sep 26.

49.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

50.

Avelumab for the treatment of metastatic Merkel cell carcinoma.

Cordes LM, Gulley JL.

Drugs Today (Barc). 2017 Jul;53(7):377-383. doi: 10.1358/dot.2017.53.7.2654888. Review.

PMID:
28837181

Supplemental Content

Loading ...
Support Center